Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
A recent study has put the safety of rosiglitazone, a widely used therapy for type 2 diabetes,under the spotlight. The study claims the treatment significantly increases the risk ofmyocardial infarction and that there is a borderline significant increased risk of death fromcardiovascular causes. However, the makers of rosiglitazone €” GlaxoSmithKline €” refutethese findings and say the study has significant limitations. Dawn Powell reviews the issues.